Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perillyl alcohol plus standard chemoradiotherapy versus standard chemoradiotherapy for glioblastoma
RBR-4ngc9n5Phase 2Recruiting
- Sponsor
- Hospital de Clínicas da Unicamp
- Start
- Nov 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of NEO100-02 in glioblastoma (GBM) (2 arms), sponsored by Hospital de Clínicas da Unicamp. Primary endpoints: Efficacy and Safety. Started Nov 2024; status: recruiting.
02
Drugs
NEO100-02
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on RBR-4ngc9n5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-4ngc9n5.